Director General of the British Generic Manufacturers Association (BGMA) and British Biosimilars Association (BBA) Warwick Smith’s reaction to NHS Improvements study on the savings delivered from 10 medicines which have switched to generics or biosimilars

Warwick Smith Director General of the British Generic Manufacturers Association and British Biosimilars Association, said: “We welcome the study from NHS Improvement which demonstrates the significant value and increased patient access both generic and biosimilar medicines deliver. Generic medicines have for a long time saved the NHS billions of pounds on an annual basis. We now see the huge value that biosimilars can also deliver to the NHS in terms of savings and increased access to patients with chronic and often long-term diseases.”

To view the full press release please visit

https://improvement.nhs.uk/news-alerts/nhs-saves-324-million-year-switching-better-value-medicines/